Literature DB >> 10204682

Effects of class III antiarrhythmic agents in an in vitro rabbit model of spontaneous torsades de pointe.

A J D'Alonzo1, J L Zhu, R B Darbenzio.   

Abstract

Acquired long QT syndrome develops as a result of pharmacological interventions that prolong action potential duration. Excessive action potential prolongation may lead to torsade de pointes, a potentially fatal arrhythmia. To study this arrhythmia, in vivo models have been developed, but are difficult to interpret due to the complex nature of the intact metabolic, nervous and humoral systems. To more clearly examine the propensity of various Class III agents to elicit torsades de pointe, an in vitro model of spontaneous torsades de pointe was used in isolated perfused rabbit hearts. Male New Zealand white rabbits were anesthetized with sodium pentobarbital, and hearts isolated and perfused in a Langendorff apparatus. Electrocardiogram and epicardial monophasic action potentials were continuously recorded, and methoxamine (30 nM) and acetylcholine (0.3 microM) were given throughout the experiment. After 10 min of methoxamine and acetylcholine perfusion, Class III agents, dofetilide (0.1 to 0.7 microM), E-4031 (0.1 to 0.5 microM), D-sotalol (10 to 30 microM), or clofilium (0.1 to 0.3 microM), were given. All agents, except D-sotalol, induced torsades de pointe in 100% of hearts tested. D-Sotalol (30 microM) elicited a low incidence of torsades de pointe (25%). This could be explained by the limited prolongation of action potential duration with D-sotalol as compared to other Class III agents under these conditions. Dofetilide, a selective Class III agent, alone did not induce torsades de pointe. Nadolol (3 microM), a beta-adrenoceptor antagonist, increased the propensity of dofetilide to elicit torsades de pointe. In conclusion, increases in action potential duration (i.e., using Class III agents) in combination with a low heart rate (muscarinic receptor stimulation) and increases in intracellular Ca2+ (alpha-adrenoceptor stimulation) are needed to develop torsades de pointe in this model. Modulating these systems may provide us with new insights into preventing the initiation or maintenance of this arrhythmia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204682     DOI: 10.1016/s0014-2999(99)00057-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Differences in action potential and early afterdepolarization properties in LQT2 and LQT3 models of long QT syndrome.

Authors:  C R Studenik; Z Zhou; C T January
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model.

Authors:  A Farkas; J Dempster; S J Coker
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

3.  An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.

Authors:  Stefan Dhein; Franziska Perlitz; Friedrich-Wilhelm Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-22       Impact factor: 3.000

4.  Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit models.

Authors:  Shailaja B Khobragade; Pankaj Gupta; Prashant Gurav; Girish Chaudhari; Madhumanjiri M Gatne; Vyas M Shingatgeri
Journal:  J Pharmacol Pharmacother       Date:  2013-04

5.  Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits.

Authors:  David Ziupa; Julia Beck; Gerlind Franke; Stefanie Perez Feliz; Maximilian Hartmann; Gideon Koren; Manfred Zehender; Christoph Bode; Michael Brunner; Katja E Odening
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.